CAPTRUST Financial Advisors
AGRX

CAPTRUST Financial Advisors’s Agile Therapeutics AGRX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2
Closed -$2K – 5243
2021
Q4 		$2K Buy
+2
New +$2.82K ﹤0.01% 4476

Other funds holding AGRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAPTRUST Financial Advisors's AGRX Position: Q1 2022 in Review

CAPTRUST Financial Advisors sold out of Agile Therapeutics (AGRX) in Q1 2022, closing a stake of 2 shares — an estimated $2K sold.

CAPTRUST Financial Advisors first reported a position in AGRX in Q4 2021 and held it in 1 quarter. The position peaked at $2K in Q4 2021. 36 funds tracked by Wall St. Rank hold AGRX as of Q1 2022.

  • CAPTRUST Financial Advisors reported no remaining Agile Therapeutics position as of Q1 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 2 Agile Therapeutics shares in Q1 2022, an estimated $2K.
  • CAPTRUST Financial Advisors first reported a position in Agile Therapeutics in Q4 2021 and held it in 1 quarter.
  • CAPTRUST Financial Advisors's Agile Therapeutics position peaked at $2K in Q4 2021.
  • 36 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2022, filed 16 May 2022.